Orlucent®, Inc. was founded by scientists and engineers who have combined expertise in oncology with advances in molecular imaging to develop a high-performance, affordable mole-evaluation system for in-office use. Globally, Orlucent has several patents issued and pending.
Read more >
Read more >
Board-certified dermatologist and clinical dermatopathologist, Professor in the Department of Dermatology at the University of Utah, and former Program Director of the Dermatology Residency Training Program. Dr. Florell works extensively with the melanoma investigators at Huntsman Cancer Institute (HCI) and received a K23 Award (2003-09) that centered around investigation of hereditary melanoma and pigmented lesions derived from subjects in Utah melanoma kindreds. His relationship with HCI includes clinical dermatopathology as well as clinical and translational research and assistance with the development of metrics to quantify pathologic and immunohistologic features in pigmented lesions. Dr. Florell was a Co-Investigator on the recently completed DOD-funded team Science Award on Mechanisms of UV-Induced Melanoma Initiation.
Investigator at the Huntsman Cancer Institute (HCI), Professor of Dermatology at the University of Utah School of Medicine, Co-Leader of the HCI Melanoma Center and director of the Mole Mapping Program at HCI. Dr. Grossman sees patients at risk for melanoma and non-melanoma skin cancer, with a special interest in patients who have hereditary melanoma and numerous and/or atypical moles. He has published extensively on the management of dysplastic nevi. Dr. Grossman’s current research is focused on development of non-invasive technologies for skin cancer diagnosis. He is principal investigator on a recently completed DOD-funded team Science Award and ongoing Translational Science Award from the V Foundation for Cancer Research.
Medical Director and Chief of Medical Dermatology for Stanford Health Care. Dr. Ko spearheads efforts around community outreach, screening and digital health. His passion for melanoma, early cancer detection, and improving care delivery drives his efforts and research around leveraging advances in machine learning and artificial intelligence to increase the breadth of populations that can be reached. He developed and runs a digital care delivery program at SHC, providing virtual visits for patients and remote consultations for referring clinicians. He conducts research on and engages in collaborations around interventions that layer advances in machine learning on digital health capabilities to enhance access, quality and value of dermatologic care and is a founder and leader of the Stanford Translational AI in Dermatology (TRAIND) group. He chairs the American Academy of Dermatology’s Committee on Augmented Intelligence.
Professor and Vice-Chair of Faculty Development in the Department of Dermatology at the University of Utah. She is a dermatologist using basic science research and state-of-the-art technology to combat skin cancer. Dr. Leachman’s clinical practice focuses primarily on skin cancer, melanoma, and genetic syndromes that increase the risk for skin cancer or other internal malignancies. She is a strong advocate for skin screenings, patient education and community outreach and has led statewide efforts in Oregon to improve early diagnosis of melanoma to reduce death due to this disease. Her research has focused on melanoma in the basic science lab, through translational human studies/trials, and in the public health arena. Dr. Leachman is the former Melanoma Program Director at the Knight Cancer Institute at Oregon Health and Science University (OHSU).
Professor of Pathology and inaugural Eugene J. Van Scott Professor in Dermatology at the University of Chicago. Dr. Shea is interested in diagnostic and experimental dermatopathology, pigmented lesions and melanoma. He is also actively engaged in the field of medical education, particularly the education and professional training of dermatology residents and dermatopathology fellows. Dr. Shea was part of the group that introduced the Duke classification system for pigmented lesions and served on the panels that developed the initial and revised standardized pathology classification system, the Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis (MPATH-Dx). As a founding member of the International Melanoma Pathology Study Group, he has performed microscopic analysis and classification of nevus and melanoma morphologic variants, including spitzoid and desmoplastic types. Dr. Shea serves on the editorial boards of the Journal of Cutaneous Pathology and the American Journal of Dermatopathology.
Currently in Clinical Trials. Research Use Only in the US.
©2025 Orlucent, Inc.
